Innovative Partnership to Enhance Alzheimer's Clinical Trials
Innovative Partnership to Enhance Alzheimer's Clinical Trials
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes
In a groundbreaking collaboration, OmniScience Inc. and INmune Bio Inc. have joined forces to transform the landscape of Alzheimer's disease clinical trials. This strategic partnership focuses on utilizing OmniScience’s innovative product, Vivo, a state-of-the-art genAI-powered control tower that centralizes and analyzes extensive clinical data in real-time, promoting immediate insights that significantly uplift decision-making processes.
Vivo's design intricately weaves together various data sources such as electronic data capture (EDC), clinical trial management systems (CTMS), patient-reported outcomes (PROs), and safety databases, among others, ensuring data integrity and accessibility for clinical teams. By integrating these diverse data streams, Vivo sets itself apart from traditional trial management tools, allowing teams to make more informed choices, expedite timelines, and enhance patient safety.
According to the Vice President of Clinical Operations at INmune Bio, Tara Lehner, the vastness of a global clinical trial necessitates robust analytical tools. "An exhaustive trial like this will rely heavily on Vivo for assessing cognitive results swiftly," she stated. With the support of genAI capabilities, Vivo allows clinical teams to rapidly convert complex data sets into practical insights, accelerating the process of bringing answers—and effective treatments—closer to patients.
Significant Advancements in Clinical Data Management
This partnership builds upon prior collaborations during the development of Vivo, which has already seen substantial benefits throughout its initial rollout phase to INmune’s clinical development teams. These improvements include:
Enhanced Data Quality and Visualization
Vivo's advanced data processing capabilities enable the automatic identification of discrepancies within data, enhancing overall data quality. Furthermore, the platform enhances the visualization of clinical outcome assessments (COAs), enabling teams to swiftly pinpoint outliers and better comprehend patient population distributions.
Real-Time Decision-Making Support
The platform is designed to facilitate real-time answers, enabling informed decisions regarding patient enrollment criteria while the patient is present. This capability reduces the need for traditional, time-consuming data analysis methods and strengthens collaboration between clinical and executive teams, improving efficacy and alignment across the board.
Vivo: A Game-Changer in Clinical Trial Operations
Angela Holmes, CEO of OmniScience, emphasized the shared vision of both companies to innovate how clinical trial teams interact with data. "Our collaboration is focused on transforming raw data into actionable knowledge quickly, which is vital for increasing the probability of success in clinical trials," she explained. Vivo is integral to this mission, continually evolving through feedback from INmune Bio's experts.
Michael Bell, VP of Product at OmniScience, also acknowledged the significant contributions of INmune Bio in shaping Vivo's capabilities. "The future of clinical trials demands smarter solutions, and Vivo exemplifies this evolution. Our hands-on collaboration ensures that users can experience firsthand the rapid transformation of data into actionable insights, redefining their workflows in the process," he noted.
About OmniScience Inc. and INmune Bio Inc.
OmniScience Inc. is paving the way for clinical research innovation, providing vital expertise through its cutting-edge technology like Vivo. The company aims to unify clinical trial data in real-time, breaking down barriers to data accessibility for improved decision-making processes. Its recognition in the industry was recently highlighted when Vivo received top honors at notable events, solidifying its position as a leader in the field.
On the other hand, INmune Bio Inc. is established as a dynamic clinical-stage biotechnology firm publicly traded on NASDAQ under the ticker INMB. Focused on harnessing the innate immune system to combat complex diseases, INmune Bio seeks to develop solutions that address pressing health challenges, especially through ongoing clinical trials targeting Alzheimer’s disease and other conditions.
Frequently Asked Questions
What is Vivo, and how does it benefit clinical trials?
Vivo is a genAI-powered control tower designed to centralize and analyze clinical trial data in real-time, enhancing decision-making and expediting trial processes.
How does the partnership between OmniScience and INmune Bio enhance Alzheimer's trials?
The partnership integrates Vivo into INmune Bio's clinical processes, facilitating real-time data analysis and improving trial management efficiency.
What are the main features of Vivo that improve data quality?
Vivo automatically identifies data discrepancies, enhances visualization of clinical outcomes, and supports real-time decision-making regarding patient enrollment.
What is INmune Bio's primary focus as a biotechnology company?
INmune Bio focuses on developing treatments that target the innate immune system to combat various diseases, particularly through their clinical programs for Alzheimer's disease.
How has Vivo been recognized in the industry?
Vivo has received top honors at significant industry events, demonstrating its innovative approach and effectiveness in enhancing clinical trial operations.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.